Overall, there was a 15.8% incidence of migraines in the first 3 months following the procedure among people randomized to clopidogrel (Plavix) plus aspirin or aspirin alone. After this initial period ...
NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...
Atrial septal defect closure techniques have evolved considerably over recent decades. Traditional surgical repair, once the mainstay of treatment for congenital heart anomalies, has gradually been ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced its development program for PerQseal ® ...
Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "PFO Closure Device Market - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. In a landscape shaped by evolving ...
The AI model was more efficient at detecting signatures of atrial septal defect (ASD) in electrocardiograms (ECG) than traditional methods. A study from Ann & Robert H. Lurie Children's Hospital of ...
Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results